NYSE:BLCO

Bausch + Lomb and Heidelberg Engineering Announce the Introduction of SeeLuma™ Fully Digital Surgical Visualization Platform

Retrieved on: 
Thursday, April 13, 2023
Technology, Surgery, Medical Devices, Health Technology, Audio, Video, Biotechnology, Health, General Health, Optical, Learning, Surgeon, Workflow, OR, Collaboration, Strategic management, Bausch & Lomb, Physician, Nursing, MSI, Ophthalmology, System, Peter Hancock (professor), Medical imaging, Camera

Bausch + Lomb, a leading global eye health company dedicated to helping people see better to live better, and Heidelberg Engineering, today announced the introduction of the SeeLuma™ Fully Digital Surgical Visualization Platform, which provides ophthalmic surgeons with a new level of visualization compared to optical, hybrid and retrofitted microscopes.

Key Points: 
  • Bausch + Lomb, a leading global eye health company dedicated to helping people see better to live better, and Heidelberg Engineering, today announced the introduction of the SeeLuma™ Fully Digital Surgical Visualization Platform, which provides ophthalmic surgeons with a new level of visualization compared to optical, hybrid and retrofitted microscopes.
  • “As part of our broader mission, Bausch + Lomb aims to provide ophthalmic surgeons around the world with innovative visualization and intraoperative diagnostic technologies that enhance the surgical experience to ultimately help deliver better patient outcomes,” said Joe Gordon, president, Global Consumer, Surgical and Vision Care, Bausch + Lomb.
  • The platform also facilitates 3D heads-up surgery using next-generation 3D 55” and 31” 4K monitors, as well as unique digital binoculars.
  • System parameters, such as zoom and focus speed, white balance, image inversion and foot control layouts, are automatically adapted to surgical steps.

Bausch + Lomb Appoints Bob Bailey as Executive Vice President and Chief Legal Officer and Andrew Stewart as President, Ophthalmic Pharmaceuticals

Retrieved on: 
Wednesday, April 12, 2023
Medical Supplies, Health, Surgery, General Health, Pharmaceutical, Optical, EVP, Bausch & Lomb, Intellectual property, General counsel, Patient, NYSE, Management

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, announced the appointments of Bob Bailey as executive vice president (EVP) and Chief Legal Officer and Andrew Stewart as president, Ophthalmic Pharmaceuticals, effective April 24, 2023.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, announced the appointments of Bob Bailey as executive vice president (EVP) and Chief Legal Officer and Andrew Stewart as president, Ophthalmic Pharmaceuticals, effective April 24, 2023.
  • Both Mr. Bailey and Mr. Stewart will join the executive management team of the Company.
  • Concurrent with these appointments, Christina Ackermann will step down from her role as EVP, General Counsel and president, Ophthalmic Pharmaceuticals, and will leave Bausch + Lomb on April 28, 2023.
  • “Bob Bailey and Andrew Stewart both bring more than 25 years of unrivaled leadership and expertise in their respective areas.

Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology

Retrieved on: 
Wednesday, March 22, 2023
Research, FDA, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Optical, Science, DED, GOBI, Research and development, Therapy, Meibomian gland dysfunction, Bausch & Lomb, Telecanthus, Development, HIV disease progression rates, Patient, American Journal of Ophthalmology, PDUFA, NYSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, MGD, Pharmaceutical industry, Dietary supplement, Ophthalmology

NOV03 is being investigated to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).

Key Points: 
  • NOV03 is being investigated to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).
  • Results from the first pivotal Phase 3 trial, GOBI, were published earlier this year in Ophthalmology .
  • The U.S. Food and Drug Administration (FDA) assigned NOV03 a Prescription Drug User Fee Act (PDUFA) action date of June 28, 2023.
  • “In addition to meeting both primary sign and symptom efficacy endpoints, NOV03 was shown to be very well tolerated in the MOJAVE study.

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2022 Results

Retrieved on: 
Wednesday, February 22, 2023
Medical Supplies, Health, Medical Devices, Surgery, Pharmaceutical, Vitamins, Supplements, Optical, EBITDA, Ophthalmology, Bausch & Lomb, SG, GAAP, EPS, Tax, Care, COGS, IPO, COVID-19, Contact, Bausch, Video game, Cryptocurrency, Pharmaceutical industry, Security (finance)

Net loss attributable to Bausch + Lomb Corporation for the fourth quarter of 2022 was $1 million, as compared to a net income attributable to Bausch + Lomb Corporation of $51 million for the fourth quarter of 2021, a decrease of $52 million.

Key Points: 
  • Net loss attributable to Bausch + Lomb Corporation for the fourth quarter of 2022 was $1 million, as compared to a net income attributable to Bausch + Lomb Corporation of $51 million for the fourth quarter of 2021, a decrease of $52 million.
  • Net income attributable to Bausch + Lomb Corporation for the full year of 2022 was $6 million, as compared to a net income attributable to Bausch + Lomb Corporation of $182 million for the full year of 2021, a decrease of $176 million.
  • GAAP EPS Basic and Diluted attributable to Bausch + Lomb Corporation for the fourth quarter of 2022 was $0.00, as compared to $0.15 for the fourth quarter of 2021.
  • Bausch + Lomb will provide expectations on its first-quarter 2023 outlook during the call today at 8 a.m.

Bausch + Lomb Appoints Brent Saunders as Chief Executive Officer and Chair of the Board of Directors, Effective March 6, 2023

Retrieved on: 
Wednesday, February 15, 2023
General Health, Health, Optical, Bausch, Bausch & Lomb, Actavis, Safety, NYSE, Patient, Brent Saunders, Allergan, Bausch Health, Schering-Plough, History, Lead, Management

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, announced the appointment of Brent Saunders as chief executive officer (“CEO”) and chair of the Board of Directors (“Board”) of the Company, effective March 6, 2023.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, announced the appointment of Brent Saunders as chief executive officer (“CEO”) and chair of the Board of Directors (“Board”) of the Company, effective March 6, 2023.
  • Additionally, effective upon Mr. Saunders’ appointment as chair of the Board, Thomas W. Ross, Sr. will become the Lead Independent Director of the Board.
  • To facilitate an orderly transition, Mr. Saunders will join Bausch + Lomb on Feb. 16, 2023, in an advisory capacity, where he will work closely with Mr. Papa.
  • Mr. Saunders will return to Bausch + Lomb after having served at the Company as CEO from 2010 to 2013.

New Bausch + Lomb Social Media Campaign Highlights What ‘Sights’ Inspire AMD Patients

Retrieved on: 
Tuesday, February 7, 2023
Social Media, Biotechnology, Optical, Managed Care, General Health, Health, Communications, Other Health, Bausch & Lomb, Paratriathlon, Smoking, NYSE, Lomb, AMD, Patient, Surgery, Fear, Risk, Anxiety, Exercise, Love, Social media, Nursing

The campaign, ‘What Sight Inspires You’, will feature personal stories and sights from Bausch + Lomb’s SightMatters community, an online educational resource designed for people living with AMD, along with educational content on AMD.

Key Points: 
  • The campaign, ‘What Sight Inspires You’, will feature personal stories and sights from Bausch + Lomb’s SightMatters community, an online educational resource designed for people living with AMD, along with educational content on AMD.
  • The campaign will run on the SightMatters Facebook page throughout the month of February.
  • “For eight years, Bausch + Lomb has supported AMD Awareness Month through a variety of campaigns.
  • “Many AMD patients feel frightened and unsettled when they are diagnosed because of what it can potentially mean for their sight and life long-term,” said Rishi Singh, staff physician and president, Cleveland Clinic Martin Hospitals, Stuart, Fla. “I applaud Bausch + Lomb for demonstrating how AMD patients can continue to live vibrantly through this year’s campaign.

Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE® (Verteporfin for Injection)

Retrieved on: 
Wednesday, February 1, 2023
Technology, Surgery, Managed Care, Medical Devices, General Health, Science, Clinical Trials, FDA, Biotechnology, Health, Health Technology, Semiconductor, Other Science, Research, Nanotechnology, Other Health, Optical, Bausch & Lomb, Ophthalmology, PDT, IPad, NYSE, AMD, Patient, Food, Choroidal neovascularization, Regulation of tobacco by the U.S. Food and Drug Administration

“PDT continues to be an important treatment option for eye care professionals who are looking to treat patients with predominantly classic subfoveal choroidal neovascularization,” said Christina Ackermann, president, Ophthalmic Pharmaceuticals, Bausch + Lomb.

Key Points: 
  • “PDT continues to be an important treatment option for eye care professionals who are looking to treat patients with predominantly classic subfoveal choroidal neovascularization,” said Christina Ackermann, president, Ophthalmic Pharmaceuticals, Bausch + Lomb.
  • “With the approval of ML6710i, eye care professionals now have a new state-of-the-art photodynamic laser that addresses a significant unmet need in PDT and is specifically designed to deliver VISUDYNE to patients who suffer from wet AMD with persistent fluid.”
    ML6710i is a modern, easy-to-use and transportable ophthalmic laser that is controlled intuitively from an iPad mobile application.
  • The laser’s beam shaping unit, which can be fit into all common slit lamps used for eye examinations, is formed into a circular, uniform spot to enable efficient treatment delivery of VISUDYNE.
  • “As a result of our efforts with Bausch + Lomb, along with the feedback that many eye care professionals provided to our teams, we are thrilled to bring forward an innovative cloud connected laser platform that the ophthalmology community can use to deliver VISUDYNE to patients in need of treatment of choroidal neovascularization due to AMD,” said Seppo Orsila, founder and CEO, Modulight.

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2022 Financial Results on February 22

Retrieved on: 
Monday, January 23, 2023
General Health, Optical, Health, Other Health, Bausch, Bausch & Lomb, NYSE, Video game, Cryptocurrency

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2022 financial results on Wednesday, Feb. 22, 2023.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2022 financial results on Wednesday, Feb. 22, 2023.
  • Bausch + Lomb will host a conference call and live web cast at 8:00 a.m.
  • ET to discuss the results and provide a business update.
  • All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call.

Bausch + Lomb Acquires AcuFocus, Inc.

Retrieved on: 
Tuesday, January 17, 2023
Medical Supplies, Medical Devices, Health, Surgery, General Health, Optical, Cataract, Severe cognitive impairment, Ageing, Presbyopia, Regulation of tobacco by the U.S. Food and Drug Administration, NYSE, Food, Growth, EDOF, Patient, Bausch & Lomb, Physician, Dioptre, Astigmatism, Multimedia, Telescopic sight, Pharmaceutical industry, IOL

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc. (“AcuFocus”), a privately held ophthalmic medical device company, today announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc. (“AcuFocus”), a privately held ophthalmic medical device company, today announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus.
  • Known as the IC-8 IOL in global markets, this IOL is available in select markets across Europe, as well as in Australia, New Zealand and Singapore.
  • Some available presbyopia-correcting IOLs have complex optics that split, shift or stretch light to provide clear vision at more than one discrete focal point.
  • “With its extensive development footprint and renowned commercial expertise, we believe Bausch + Lomb is best positioned to educate physicians about the IC-8 Apthera lens, and ultimately, ensure more cataract patients have access to this new IOL.”

Bausch + Lomb Introduces Enhanced PreserVision® AREDS 2 Formula Mini Soft Gels with OCUSorb™

Retrieved on: 
Monday, January 9, 2023
Medical Supplies, Health, General Health, Pharmaceutical, Vitamins, Supplements, Optical, Biotechnology, AREDS, Severe cognitive impairment, Formula, National Eye Institute, Risk, Antioxidant, NYSE, AMD, NEI, Patient, Bausch & Lomb, HIV disease progression rates, Research, Multimedia, Nutrient, Lutein, Surgery, Exercise, Cosmetics, Dietary supplement

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. introduction of PreserVision® AREDS 2 Formula mini soft gels with OCUSorb™.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. introduction of PreserVision® AREDS 2 Formula mini soft gels with OCUSorb™.
  • This product is the only AREDS 2 eye vitamin with the OCUSorb formulation.
  • I am pleased to recommend this new enhanced formula to my patients.”‡*
    PreserVision® AREDS 2 Formula eye vitamins, including the new OCUSorb formula, contain the exact nutrient formula recommended by the National Eye Institute (NEI).
  • “We remain committed to supporting and providing the nearly 16 million Americans affected by AMD with products that address their eye health needs.”
    PreserVision AREDS 2 Formula mini soft gels with OCUSorb are now available at most major retailers nationwide in the vitamin aisle or online and will replace the current PreserVision AREDS 2 Formula mini gel formula.